TL1A(TNF配体相关分子1A)是肿瘤坏死因子超家族的成员，主要由内皮细胞表达。它与DR3(死亡受体3)结合，为下游信号通路提供刺激信号，调节效应细胞的增殖、活化、凋亡和细胞因子、趋化因子的产生。作为粘膜免疫反应、过敏和自身免疫的中枢调节因子，TL1A/DR3在 ...

a first-in-class DR3 antagonist antibody designed to achieve complete and durable blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham ...

Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist ...

a first-in-class DR3 antagonist antibody designed to achieve complete and durable blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham ...

a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham ...

Shattuck's expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

TL1A（TNF配体相关分子1A）是肿瘤坏死因子超家族的成员，主要由内皮细胞表达。它与DR3（死亡受体3）结合，为下游信号通路提供刺激信号，调节效应 ...